• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Non-tremor motor dysfunction in Lewy body dementias is associated with AD biomarkers.路易体痴呆的非震颤运动功能障碍与 AD 生物标志物相关。
Parkinsonism Relat Disord. 2022 Jul;100:33-36. doi: 10.1016/j.parkreldis.2022.05.022. Epub 2022 Jun 8.
2
Do Alzheimer's and Lewy body disease have discrete pathological signatures of gait?阿尔茨海默病和路易体病的步态是否具有不同的病理学特征?
Alzheimers Dement. 2019 Oct;15(10):1367-1377. doi: 10.1016/j.jalz.2019.06.4953. Epub 2019 Sep 20.
3
Neuropsychiatric symptoms profile and markers of Alzheimer disease-type pathology in patients with Lewy body dementias.路易体痴呆患者的神经精神症状特征和阿尔茨海默病型病理标志物。
Brain Res. 2024 Jun 15;1833:148881. doi: 10.1016/j.brainres.2024.148881. Epub 2024 Mar 21.
4
Motor performance differentiates individuals with Lewy body dementia, Parkinson's and Alzheimer's disease.运动表现可区分路易体痴呆、帕金森病和阿尔茨海默病患者。
Gait Posture. 2016 Oct;50:1-7. doi: 10.1016/j.gaitpost.2016.08.009. Epub 2016 Aug 11.
5
CSF tau and β-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders.脑脊液 tau 和 β-淀粉样蛋白可预测尸检路易体病中的脑突触核蛋白病。
Neurology. 2018 Mar 20;90(12):e1038-e1046. doi: 10.1212/WNL.0000000000005166. Epub 2018 Feb 21.
6
Clinical and diagnostic implications of Alzheimer's disease copathology in Lewy body disease.路易体病中阿尔茨海默病共病的临床和诊断意义。
Brain. 2024 Oct 3;147(10):3325-3343. doi: 10.1093/brain/awae203.
7
Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort.路易体疾病谱系中的脑脊液阿尔茨海默病生物标志物:一项大型多中心队列研究结果
J Alzheimers Dis. 2016 Aug 18;54(1):287-95. doi: 10.3233/JAD-160322.
8
In vivo detection of Alzheimer's and Lewy body disease concurrence: Clinical implications and future perspectives.在体检测阿尔茨海默病和路易体病共存:临床意义和未来展望。
Alzheimers Dement. 2024 Aug;20(8):5757-5770. doi: 10.1002/alz.14039. Epub 2024 Jun 21.
9
How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: comparison with the unified Parkinson's disease rating scale.如何使用运动障碍学会统一帕金森病评定量表识别震颤为主型和姿势不稳/步态困难型:与统一帕金森病评定量表的比较。
Mov Disord. 2013 May;28(5):668-70. doi: 10.1002/mds.25383. Epub 2013 Feb 13.
10
Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson's disease.血浆神经丝轻链作为早期帕金森病姿势不稳步态障碍运动亚型的诊断和预后生物标志物的效用。
Mol Neurodegener. 2020 Jun 5;15(1):33. doi: 10.1186/s13024-020-00385-5.

引用本文的文献

1
Relationships among cortical activation, cognition, and blood biomarkers in two types of dementia determined using functional near-infrared spectroscopy.使用功能近红外光谱法确定的两种痴呆类型中皮质激活、认知和血液生物标志物之间的关系。
Front Neurol. 2025 Apr 14;16:1488420. doi: 10.3389/fneur.2025.1488420. eCollection 2025.
2
Aβ42 biomarker linked to insula, striatum, thalamus and claustrum in dementia with Lewy bodies.在路易体痴呆中,β淀粉样蛋白42生物标志物与脑岛、纹状体、丘脑和屏状核相关。
Geroscience. 2025 Jan 17. doi: 10.1007/s11357-025-01513-z.
3
ADNI Biomarker Core: A review of progress since 2004 and future challenges.ADNI生物标志物核心:2004年以来的进展回顾与未来挑战
Alzheimers Dement. 2025 Jan;21(1):e14264. doi: 10.1002/alz.14264. Epub 2024 Nov 30.
4
Impaired Gait, Postural Instability, and Rigidity in Relation to CB1 Receptor Availability in Parkinson's Disease.帕金森病中与CB1受体可用性相关的步态障碍、姿势不稳和僵硬
Mov Disord. 2025 Jan;40(1):163-167. doi: 10.1002/mds.30042. Epub 2024 Oct 22.
5
Plasma GFAP as a prognostic biomarker of motor subtype in early Parkinson's disease.血浆胶质纤维酸性蛋白作为早期帕金森病运动亚型的预后生物标志物。
NPJ Parkinsons Dis. 2024 Mar 1;10(1):48. doi: 10.1038/s41531-024-00664-8.
6
Fluid and Biopsy Based Biomarkers in Parkinson's Disease.基于液体和活检的帕金森病生物标志物。
Neurotherapeutics. 2023 Jul;20(4):932-954. doi: 10.1007/s13311-023-01379-z. Epub 2023 May 3.
7
Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease.血浆 GFAP 与路易体病中的阿尔茨海默病二级病理相关。
Ann Clin Transl Neurol. 2023 May;10(5):802-813. doi: 10.1002/acn3.51768. Epub 2023 Mar 31.

本文引用的文献

1
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.NIA-AA 研究框架:迈向阿尔茨海默病的生物学定义。
Alzheimers Dement. 2018 Apr;14(4):535-562. doi: 10.1016/j.jalz.2018.02.018.
2
CSF tau and β-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders.脑脊液 tau 和 β-淀粉样蛋白可预测尸检路易体病中的脑突触核蛋白病。
Neurology. 2018 Mar 20;90(12):e1038-e1046. doi: 10.1212/WNL.0000000000005166. Epub 2018 Feb 21.
3
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium.路易体痴呆的诊断与管理:DLB联盟第四次共识报告
Neurology. 2017 Jul 4;89(1):88-100. doi: 10.1212/WNL.0000000000004058. Epub 2017 Jun 7.
4
Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis.突触核蛋白病生存及痴呆症发病的神经病理学和遗传学关联:一项回顾性分析
Lancet Neurol. 2017 Jan;16(1):55-65. doi: 10.1016/S1474-4422(16)30291-5.
5
Simplified conversion method for unified Parkinson's disease rating scale motor examinations.统一帕金森病评定量表运动检查的简化转换方法。
Mov Disord. 2015 Dec;30(14):1967-70. doi: 10.1002/mds.26435. Epub 2015 Nov 17.
6
Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.脑脊液β-淀粉样蛋白 1-42、T 蛋白、P 蛋白 181 和α-突触核蛋白水平与未经药物治疗的早期帕金森病患者临床特征的关系。
JAMA Neurol. 2013 Oct;70(10):1277-87. doi: 10.1001/jamaneurol.2013.3861.
7
Association between male gender and cortical Lewy body pathology in large autopsy series.男性性别与大型尸检系列中皮质路易体病理的关联。
J Neurol. 2010 Nov;257(11):1875-81. doi: 10.1007/s00415-010-5630-4. Epub 2010 Jun 20.
8
A clinico-pathological study of subtypes in Parkinson's disease.帕金森病亚型的临床病理研究。
Brain. 2009 Nov;132(Pt 11):2947-57. doi: 10.1093/brain/awp234. Epub 2009 Sep 16.
9
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.阿尔茨海默病神经影像学计划受试者的脑脊液生物标志物特征
Ann Neurol. 2009 Apr;65(4):403-13. doi: 10.1002/ana.21610.
10
Clinical diagnostic criteria for dementia associated with Parkinson's disease.帕金森病相关痴呆的临床诊断标准。
Mov Disord. 2007 Sep 15;22(12):1689-707; quiz 1837. doi: 10.1002/mds.21507.

路易体痴呆的非震颤运动功能障碍与 AD 生物标志物相关。

Non-tremor motor dysfunction in Lewy body dementias is associated with AD biomarkers.

机构信息

University of Pennsylvania, Department of Neurology, Philadelphia, PA, 19104, United States.

University of Pennsylvania, Department of Neurology, Philadelphia, PA, 19104, United States; Michael J. Crescenz VA Medical Center, Parkinson's Disease Research, Education, and Clinical Center, Philadelphia, PA, 19104, United States.

出版信息

Parkinsonism Relat Disord. 2022 Jul;100:33-36. doi: 10.1016/j.parkreldis.2022.05.022. Epub 2022 Jun 8.

DOI:10.1016/j.parkreldis.2022.05.022
PMID:35700626
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10078247/
Abstract

Motor features of Parkinson's disease (PD) are heterogeneous and well-studied; non-tremor features of postural instability and gait dysfunction (PIGD) have been linked to worse outcomes and Alzheimer's disease (AD) co-pathology. However, these features are understudied in Lewy body dementias (LBD). Here we perform retrospective analysis of a unique cohort of LBD (n = 30) with Unified Parkinson's Disease Rating Scale (UPDRS) data collected at baseline in proximity to cerebrospinal fluid collection to test the hypothesis that LBD patients with a positive AD biomarker profile (LBD + AD = 13) would have higher PIGD burden compared with LBD patients without AD biomarker positivity (LBD-AD = 17). We find novel evidence for selective impairment of PIGD burden in LBD + AD vs LBD-AD (OR = 1.95, 95%CI = 1.02-3.70, p = 0.04) and a direct association of increasing CSF tau/Aβ ratio with increasing PIGD disability in the total cohort (β = 0.23, SE = 0.08, p = 0.01). This unique biomarker stratification approach suggests AD co-pathology may contribute to PIGD motor signs in LBD.

摘要

帕金森病(PD)的运动特征具有异质性,并且已经得到了充分的研究;姿势不稳和步态功能障碍(PIGD)等非震颤特征与较差的预后和阿尔茨海默病(AD)共病有关。然而,这些特征在路易体痴呆症(LBD)中研究较少。在这里,我们对一组独特的 LBD 患者(n=30)进行了回顾性分析,这些患者在靠近脑脊液采集时收集了基线统一帕金森病评定量表(UPDRS)数据,以检验以下假设:具有 AD 生物标志物阳性特征的 LBD 患者(LBD+AD=13)与没有 AD 生物标志物阳性特征的 LBD 患者(LBD-AD=17)相比,PIGD 负担更高。我们发现了新的证据,表明 LBD+AD 与 LBD-AD 相比,PIGD 负担存在选择性损伤(OR=1.95,95%CI=1.02-3.70,p=0.04),并且在总队列中,CSF tau/Aβ 比值的增加与 PIGD 残疾的增加呈直接关联(β=0.23,SE=0.08,p=0.01)。这种独特的生物标志物分层方法表明,AD 共病可能导致 LBD 中的 PIGD 运动体征。